HRP980114A2 - Chemical compound - Google Patents

Chemical compound

Info

Publication number
HRP980114A2
HRP980114A2 HR9704498.6A HRP980114A HRP980114A2 HR P980114 A2 HRP980114 A2 HR P980114A2 HR P980114 A HRP980114 A HR P980114A HR P980114 A2 HRP980114 A2 HR P980114A2
Authority
HR
Croatia
Prior art keywords
compound
hydrated form
crystalline hydrated
sodium salt
alkyl ester
Prior art date
Application number
HR9704498.6A
Other languages
English (en)
Croatian (hr)
Inventor
Paolo Maragini
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of HRP980114A2 publication Critical patent/HRP980114A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR9704498.6A 1997-03-05 1998-03-04 Chemical compound HRP980114A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9704498.6A GB9704498D0 (en) 1997-03-05 1997-03-05 Chemical compound

Publications (1)

Publication Number Publication Date
HRP980114A2 true HRP980114A2 (en) 1998-12-31

Family

ID=10808697

Family Applications (1)

Application Number Title Priority Date Filing Date
HR9704498.6A HRP980114A2 (en) 1997-03-05 1998-03-04 Chemical compound

Country Status (29)

Country Link
EP (1) EP0966463A1 (fr)
JP (1) JP2001513796A (fr)
KR (1) KR20000075907A (fr)
CN (1) CN1249750A (fr)
AP (1) AP9901637A0 (fr)
AR (1) AR011178A1 (fr)
AU (1) AU6825198A (fr)
BG (1) BG103779A (fr)
BR (1) BR9808305A (fr)
CA (1) CA2282851A1 (fr)
CO (1) CO4940415A1 (fr)
EA (1) EA199900710A1 (fr)
EE (1) EE9900387A (fr)
GB (1) GB9704498D0 (fr)
HR (1) HRP980114A2 (fr)
HU (1) HUP0002109A2 (fr)
ID (1) ID24207A (fr)
IL (1) IL131489A0 (fr)
IS (1) IS5166A (fr)
NO (1) NO994303L (fr)
NZ (1) NZ337315A (fr)
OA (1) OA11154A (fr)
PE (1) PE51399A1 (fr)
PL (1) PL335652A1 (fr)
SK (1) SK119699A3 (fr)
TR (1) TR199902117T2 (fr)
WO (1) WO1998039327A1 (fr)
YU (1) YU43499A (fr)
ZA (1) ZA981791B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
GB9704498D0 (en) 1997-04-23
WO1998039327A1 (fr) 1998-09-11
BR9808305A (pt) 2000-05-16
EP0966463A1 (fr) 1999-12-29
ID24207A (id) 2000-07-13
EE9900387A (et) 2000-04-17
CO4940415A1 (es) 2000-07-24
PE51399A1 (es) 1999-06-07
IS5166A (is) 1999-08-27
IL131489A0 (en) 2001-01-28
AU6825198A (en) 1998-09-22
SK119699A3 (en) 2000-05-16
KR20000075907A (ko) 2000-12-26
ZA981791B (en) 1999-09-03
TR199902117T2 (xx) 2000-03-21
NO994303L (no) 1999-11-03
PL335652A1 (en) 2000-05-08
JP2001513796A (ja) 2001-09-04
OA11154A (en) 2003-04-16
CN1249750A (zh) 2000-04-05
NO994303D0 (no) 1999-09-03
AP9901637A0 (en) 1999-09-30
YU43499A (sh) 2000-12-28
NZ337315A (en) 2001-02-23
EA199900710A1 (ru) 2000-04-24
AR011178A1 (es) 2000-08-02
BG103779A (en) 2000-06-30
CA2282851A1 (fr) 1998-09-11
HUP0002109A2 (hu) 2001-04-28

Similar Documents

Publication Publication Date Title
US5374648A (en) Indole derivatives and pharmaceutical use thereof
CN101362765B (zh) 具有PDE-5抑制活性的5,7-二氨基吡唑并[4,3-d]嘧啶
TWI540133B (zh) 嘧啶衍生物之製造方法
EA027855B1 (ru) Соединения и способы для противовирусной терапии
EP1799208A2 (fr) Composes aromatiques heterocycliques utilises comme secretagogues d'hormone de croissance
WO2017028816A1 (fr) Dérivé d'indole, son procédé de préparation et son utilisation dans un médicament pharmaceutique
JPH09503770A (ja) Ｎｍｄａアンタゴニストとしてのインドール誘導体
CZ413991A3 (en) Bicyclic compounds, their salts, solvates, hydrates and esters
EP4232431B1 (fr) Composés et compositions pour traiter des états pathologiques associés à l'activité du récepteur lpa
CN104854093A (zh) 新的选择性雄激素受体调节剂
CA2949663A1 (fr) Derives de dipicolylamine et leurs utilisations pharmaceutiques
HRP20000845A2 (en) Tetrahydroquinoline derivatives as glycine antagonists
HUP0002109A2 (hu) (E)-4,6-diklór-3-(2-oxo-1-fenilpirrolidin-3-ilidén-metil)-1H-indol-2-karbonsav kristályos hidratált nátriumsója, eljárás előállítására és az ilyen vegyületet tartalmazó gyógyszerkészítmény
NZ337793A (en) Quinoline-2-carboxylic acid derivatives and the use of these derivatives in the preparation of medicaments for antagonising the effect of excitatory amino acids upon the NMDA receptor complex
CN1325488C (zh) 杂环衍生物
CZ314799A3 (cs) Krystalická hydratovaná sodná sůl kyseliny (E)-4,6-dichlor-3-(2-oxo-l-fenylpyrrolidin-3- ylidenmethyl)-lH-indol-2-karboxylové
HK40101053B (en) Compounds and compositions for treating conditions associated with lpa receptor activity
HK40101053A (en) Compounds and compositions for treating conditions associated with lpa receptor activity
HK1128917B (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity
CZ340599A3 (cs) Derivát kyseliny chinolin-2-karboxylové
HK1189888A (en) Intermediates for preparing indole benzylamine compound
HK1156598B (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
HK1156598A1 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
HK1220686B (en) Crystalline forms of 5-(2,6-di-4-morpholinyl-4-pyridmidinyl)-4-trifluoromethylpyridin-2-amine, a pik3 inhibitor

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20010304

Year of fee payment: 4

ODBI Application refused